The CoC National Cancer Database will release five new quality measures to the Rapid Cancer Reporting System (RCRS) platform. An official release date will be announced shortly, and accredited programs will be notified as to when the measure specifications are available in the RCRS library.
- For patients greater than or equal to age 70, grade 1-2, hormone receptor positive and HER2-negative invasive breast carcinoma with tumor size less than or equal to 2 cm and American Joint Committee on Cancer (AJCC) clinical N0, who underwent breast conserving surgery, a sentinel lymph node biopsy or axillary lymph node dissection was not performed.
- For patients with newly diagnosed oropharyngeal squamous cell carcinoma, p16 status by immunohistochemistry is documented.
- Patients with pancreatic ductal adenocarcinoma that is stage I or II and underwent curative surgery should have no residual tumor after resection of the primary.
- For patients with stage I or II cholangiocarcinoma (BTC) or pancreatic ductal adenocarcinoma (PDAC), who had upfront curative surgery, adjuvant chemotherapy is initiated within 6 months, or recommended.
- For hepatocellular carcinoma of any stage, alpha fetoprotein (AFP) is obtained at diagnosis.
For questions, contact ncdb@facs.org